QUALITY OF LIVE IN PATIENTS WITH CML: QUESTIONNAIRE BASED STUDY
(Abstract release date: 05/21/15)
EHA Library. Kim K. 06/12/15; 102991; PB1763
Disclosure(s): Soonchunhyang University Hospital
Kyoung Ha Kim
Contributions
Contributions
Abstract
Abstract: PB1763
Type: Publication Only
Background
With imatinib therapy, the survival of patients with CML has improved dramatically. In recent years, second generation TKI (2G TKI) led to more increased responses. Despite the demonstrated superiority of efficacy and toxicities as previous treatments, several adverse events of TKIs remain. Because CML treatment is lifelong, it is important for patients to maintain adherent to treatment. Correlations between poor adherence to TKI treatment and adverse events and quality of life (QoL) have been demonstrated among CML patients in clinical settings. The FACT-leu is a validated tool that measures leukemia-specific and more general QoL concerns. However, there are few studies about QoL of CML patients in Korea.
Aims
Therefore, we evaluated the QoL of CML patients treated with TKIs.
Methods
The CML working party of the Korean society of Hematology was produced by the questionnaire included the questions of FACT-leu. We distributed the questionnaire over the online or offline. QoL of patients with CML was analyzed using these questionnaires.
Results
A total of 384 patients responded to the survey between March 2014 and June 2014. Patients with high compliance of TKI (taking 90% or more drugs) were 88.28% and lower compliance (taking 70% or less drugs) were 1.82%. In queries about poor adherence to TKI therapy, most common cause was forgetfulness (18.49%). FACT-Leu scale was higher in patients with 2G TKIs than imatinib (122.9 ± 22.65 vs 116.0 ± 25.00 (p=0.005)). Female, older patients showed meaningful worse QoL in FACT-leu scale.
Summary
In 2G TKI era, QoL of CML patients seemed that is better than before. Additional prospective studies are warranted using adequate measuring tool of QoL.
Keyword(s): Quality of life
Session topic: Publication Only
Type: Publication Only
Background
With imatinib therapy, the survival of patients with CML has improved dramatically. In recent years, second generation TKI (2G TKI) led to more increased responses. Despite the demonstrated superiority of efficacy and toxicities as previous treatments, several adverse events of TKIs remain. Because CML treatment is lifelong, it is important for patients to maintain adherent to treatment. Correlations between poor adherence to TKI treatment and adverse events and quality of life (QoL) have been demonstrated among CML patients in clinical settings. The FACT-leu is a validated tool that measures leukemia-specific and more general QoL concerns. However, there are few studies about QoL of CML patients in Korea.
Aims
Therefore, we evaluated the QoL of CML patients treated with TKIs.
Methods
The CML working party of the Korean society of Hematology was produced by the questionnaire included the questions of FACT-leu. We distributed the questionnaire over the online or offline. QoL of patients with CML was analyzed using these questionnaires.
Results
A total of 384 patients responded to the survey between March 2014 and June 2014. Patients with high compliance of TKI (taking 90% or more drugs) were 88.28% and lower compliance (taking 70% or less drugs) were 1.82%. In queries about poor adherence to TKI therapy, most common cause was forgetfulness (18.49%). FACT-Leu scale was higher in patients with 2G TKIs than imatinib (122.9 ± 22.65 vs 116.0 ± 25.00 (p=0.005)). Female, older patients showed meaningful worse QoL in FACT-leu scale.
Summary
In 2G TKI era, QoL of CML patients seemed that is better than before. Additional prospective studies are warranted using adequate measuring tool of QoL.
Keyword(s): Quality of life
Session topic: Publication Only
Abstract: PB1763
Type: Publication Only
Background
With imatinib therapy, the survival of patients with CML has improved dramatically. In recent years, second generation TKI (2G TKI) led to more increased responses. Despite the demonstrated superiority of efficacy and toxicities as previous treatments, several adverse events of TKIs remain. Because CML treatment is lifelong, it is important for patients to maintain adherent to treatment. Correlations between poor adherence to TKI treatment and adverse events and quality of life (QoL) have been demonstrated among CML patients in clinical settings. The FACT-leu is a validated tool that measures leukemia-specific and more general QoL concerns. However, there are few studies about QoL of CML patients in Korea.
Aims
Therefore, we evaluated the QoL of CML patients treated with TKIs.
Methods
The CML working party of the Korean society of Hematology was produced by the questionnaire included the questions of FACT-leu. We distributed the questionnaire over the online or offline. QoL of patients with CML was analyzed using these questionnaires.
Results
A total of 384 patients responded to the survey between March 2014 and June 2014. Patients with high compliance of TKI (taking 90% or more drugs) were 88.28% and lower compliance (taking 70% or less drugs) were 1.82%. In queries about poor adherence to TKI therapy, most common cause was forgetfulness (18.49%). FACT-Leu scale was higher in patients with 2G TKIs than imatinib (122.9 ± 22.65 vs 116.0 ± 25.00 (p=0.005)). Female, older patients showed meaningful worse QoL in FACT-leu scale.
Summary
In 2G TKI era, QoL of CML patients seemed that is better than before. Additional prospective studies are warranted using adequate measuring tool of QoL.
Keyword(s): Quality of life
Session topic: Publication Only
Type: Publication Only
Background
With imatinib therapy, the survival of patients with CML has improved dramatically. In recent years, second generation TKI (2G TKI) led to more increased responses. Despite the demonstrated superiority of efficacy and toxicities as previous treatments, several adverse events of TKIs remain. Because CML treatment is lifelong, it is important for patients to maintain adherent to treatment. Correlations between poor adherence to TKI treatment and adverse events and quality of life (QoL) have been demonstrated among CML patients in clinical settings. The FACT-leu is a validated tool that measures leukemia-specific and more general QoL concerns. However, there are few studies about QoL of CML patients in Korea.
Aims
Therefore, we evaluated the QoL of CML patients treated with TKIs.
Methods
The CML working party of the Korean society of Hematology was produced by the questionnaire included the questions of FACT-leu. We distributed the questionnaire over the online or offline. QoL of patients with CML was analyzed using these questionnaires.
Results
A total of 384 patients responded to the survey between March 2014 and June 2014. Patients with high compliance of TKI (taking 90% or more drugs) were 88.28% and lower compliance (taking 70% or less drugs) were 1.82%. In queries about poor adherence to TKI therapy, most common cause was forgetfulness (18.49%). FACT-Leu scale was higher in patients with 2G TKIs than imatinib (122.9 ± 22.65 vs 116.0 ± 25.00 (p=0.005)). Female, older patients showed meaningful worse QoL in FACT-leu scale.
Summary
In 2G TKI era, QoL of CML patients seemed that is better than before. Additional prospective studies are warranted using adequate measuring tool of QoL.
Keyword(s): Quality of life
Session topic: Publication Only
{{ help_message }}
{{filter}}